Superior B-cell Repertoire Profiling Platform
- I-STAR™ allows rapid identification of broadly neutralizing and potent, therapeutic monoclonal antibodies
- Antibodies are human-derived via interrogation of the memory B-cell repertoire
- Speeds discovery of novel, rare and conformational epitopes
- Multiple disease indications
- Augments vaccine development

Valuable Product Development Pipeline
- Current focus is infectious disease and cancer
- Strategic partnerships with Pfizer, Zenyaku Kogyo Co, Ltd. and the International AIDS Vaccine Initiative (IAVI)
- Product candidate development programs include: Influenza and human cytomegalovirus (HCMV)
- Preclinical development programs include: Oncology, Rhinovirus, HIV, and other infectious disease targets

I-STAR™ Platform Yields Therapeutic Antibody Pipeline

<table>
<thead>
<tr>
<th>Infectious Disease</th>
<th>Discovery Stage</th>
<th>Preclinical Development</th>
<th>Phase 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pandemic and Seasonal Influenza (M2e)</td>
<td>TCN-032</td>
<td>ZK® Japan</td>
<td></td>
</tr>
<tr>
<td>Hemagglutinin (HA)</td>
<td></td>
<td>ZK® Japan</td>
<td></td>
</tr>
<tr>
<td>HCMV (HA)</td>
<td>TCN-202</td>
<td>IAVI*</td>
<td></td>
</tr>
<tr>
<td>HIV</td>
<td></td>
<td>Pfizer*</td>
<td></td>
</tr>
<tr>
<td>Rhinovirus - Asthma/COPD</td>
<td></td>
<td>Pfizer*</td>
<td></td>
</tr>
<tr>
<td>Undisclosed target</td>
<td></td>
<td>Pfizer*</td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td>Undisclosed target</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Funded Partnership

Influenza Program
Theraclone is developing human antibodies as acute-use therapeutics for the treatment of severe hospitalized flu and for the national pandemic stockpile. Research is focused on two influenza targets: M2e and hemagglutinin (HA).

M2e:
TCN-032 is an IgG monoclonal antibody that binds to a novel conformational epitope on the N-terminus of the M2e protein. The epitope recognized by TCN-032 is conserved in over 98% of known influenza A strains, including avian and swine strains. TCN-032 binds influenza virus and infected cells and has demonstrated potent protection in vivo against H5N1 and 2009 S-OIV H1N1 influenza strains. A Phase 1 clinical trial is ongoing with top line results expected in Q2 2012. A Phase 2 viral challenge study is planned in H2 2012.

HA:
Theraclone is screening human donors for broadly neutralizing, cross-reactive human antibodies to hemagglutinin. To date, several candidates have been identified that bind and broadly neutralize Group 1 as well as the H3 subtype of Group 2 influenza strains.

PNAS, 107, pp12658, 2010

HCMV Program
Human cytomegalovirus (HCMV) disease remains an unmet medical need: In the US, the estimated prevalence of congenital HCMV infection is ~1% and is one of the leading causes of permanent hearing loss and neurological deficits in children. In immunocompromised individuals such as transplant recipients it can cause serious life-threatening disease and may significantly increase the risk of graft rejection.

With the goal of developing safer and more effective therapy, Theraclone has isolated and characterized a potent, neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV: TCN-202.

TCN-202 neutralizes HCMV infection in many cell types including epithelial cells, endothelial cells, and fibroblasts, as well as across multiple viral strains, including primary clinical isolates. In preclinical studies, TCN-202 demonstrated efficacy in an in vivo animal model of HCMV infection. A Phase 1 study is anticipated to commence in H2 2012.
**Human Rhinovirus Program**

In patients with chronic respiratory disease such as asthma, COPD and cystic fibrosis, human rhinovirus (HRV) infection is the most common cause for exacerbation of disease, leading to increased hospitalization and mortality. Thus, there remains a great need for more effective therapy and prophylaxis in high risk patient groups. Theraclone has identified a panel of broadly neutralizing monoclonal antibodies with ongoing discovery efforts to identify additional therapeutic candidates.

**HIV bNAb / Vaccine Discovery Collaboration**

Broadly neutralizing antibodies derived from rare individuals with protective immunity against HIV provide clues to important epitopes. Theraclone has been collaborating with IAVI to examine the B-cell repertoires of these HIV-infected, long-term non-progressing patients. Through this collaboration, Theraclone has discovered over 16 of the most potent and broadly relevant antibodies to be identified in over 20 years of HIV research. Epitopes identified through characterization of these antibodies will be tested as vaccine candidates by IAVI.


---

**Management**

Clifford J. Stocks, Chief Executive Officer  
Eleanor Ramos, MD, Chief Medical Officer  
Kristine Swiderek, PhD, Chief Scientific Officer  
Russ Hawkinson, Chief Financial Officer

**Board of Directors**

Chairman: Steven Gillis, PhD, ARCH Venture Partners  
Wende Hutton, Canaan Ventures  
Chris Mirabelli, PhD, Healthcare Ventures  
William Greene, MD, MPM Capital

**Investors**

ARCH Venture Partners  
Canaan Partners  
Healthcare Ventures  
MPM Capital

**Strategic Collaborations**

Theraclone has ongoing collaborations with:

- Pfizer on select oncology and infectious disease targets;
- Zenyaku Kogyo (Japan rights only) on Influenza; and,
- IAVI on HIV vaccine development.
- Theraclone is seeking strong strategic alliances focused on discovery and development of therapeutically important antibody and vaccine products.

**Contact Information**

Attn: Russ Hawkinson, CFO  
Theraclone Sciences, Inc.  
1124 Columbia Street, Suite 300  
Seattle, WA 98104  
Tel: 206 805 1617  
rhawkinson@theraclone-sciences.com